Drug intelligence / Profile preview

AVN-492

Development stage: Preclinical
Lead developer: Avineuro Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

AVN-492 is a novel, highly potent, and highly selective small molecule 5-HT6 receptor antagonist developed by Avineuro Pharmaceuticals for the treatment of central nervous system (CNS) diseases. It exhibits an exceptionally high affinity for the 5-HT6 receptor (Ki = 91 pM), showing over 1,000-fold selectivity over the 5-HT2B receptor. Preclinical evaluations in rodents have shown that AVN-492 possesses high oral bioavailability and excellent brain permeability. The compound is being investigated as a potential therapeutic for cognitive and neurodegenerative impairments associated with conditions such as Alzheimer's disease and schizophrenia, currently serving as a backup candidate in the company's pipeline.

Targets

HTR6 (5-hydroxytryptamine receptor 6)HTR2B (5-Hydroxytryptamine Receptor 2B)

Beyond the preview

Go deeper on AVN-492.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVN-492.

Explore the full profile